NCT06279767 is a Phase 1, PHASE2 clinical trial of 6-mercaptopurine in Glioblastoma, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT06279767?

NCT06279767 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT06279767?

Interventions in NCT06279767: 6-mercaptopurine.

What condition does NCT06279767 study?

NCT06279767 studies Glioblastoma, Cancer, Temozolomide.

Is NCT06279767 still recruiting?

NCT06279767 is currently status unknown. Last updated 28 February 2024.

Last reviewed 2024-02-28 · How we verify

NCT06279767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

Status unknown Phase 1, PHASE2 Last updated 28 February 2024

What this trial tests

Phase 1, PHASE2 trial testing 6-mercaptopurine in Glioblastoma in 27 participants. Status unknown.

Timeline

1 July 2022

Primary endpoint
1 July 2025

31 July 2025

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	1 July 2022
Primary completion	1 July 2025
Estimated completion	31 July 2025
Sites	1 location across China

Drugs / interventions tested

6-mercaptopurine (6-mercaptopurine) — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Cancer — all drugs for Cancer →
Temozolomide — all drugs for Temozolomide →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 65, any sex, with Glioblastoma or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Glioblastoma, the most prevalent malignant tumor in the central nervous system, is characterized by high invasiveness and a propensity to recur, contributing to a relatively elevated mortality rate. Patients diagnosed with high-grade glioblastomas typically experience a median survival period of less than 14 months. Presently, the standard treatment for glioblastoma involves surgical resection combined with postoperative radiotherapy and chemotherapy, with postoperative chemotherapy playing a pivotal role in enhancing patient prognosis. Temozolomide (TMZ), a cutting-edge oral alkylating agent known for its advantageous properties, including easy traversal of the blood-brain barrier, induces DNA alkylation in tumor cells, fostering apoptosis. Currently, it serves as a frontline medication for postoperative chemotherapy in glioblastoma. However, clinical resistance to TMZ chemotherapy significantly hampers its efficacy in later stages. We have recently discovered and validated that 5-aminoimidazole-4-carboxamide (AICA), derived from TMZ, can transform into 5-aminoimidazole-4-carboxamide ribonucleotide-5-phosphate (AICAR) in GBM cells. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) has been identified as the catalyst for the AICA reaction, generating AICAR. AICAR acts as an endogenous activator of AMP-activated protein kinase (AMPK), fostering chemoresistance in glioblastoma through the activation of the AMPK signaling pathway. 6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity, thereby impeding TMZ-induced AMPK activation and significantly heightening glioblastoma cell sensitivity to TMZ. In this project, we propose an innovative strategy involving the combination of 6-MP with TMZ for the treatment of glioblastoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Metabolic reprogramming in cancer and senescence.
Zhang Y, Tang J, Jiang C, Yi H, et al · · 2025 · cited 13× · PMID 40046406 · DOI 10.1002/mco2.70055

Verify or expand the search:

Other trials of 6-mercaptopurine

Trials testing the same drug.

NCT06387121 — Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL · Phase 2 · recruiting
NCT05660473 — Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromoso · Phase 2 · recruiting
NCT04228393 — The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China · Phase 2, PHASE3 · unknown
NCT03384654 — A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equ · Phase 2 · completed

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06279767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 28 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06279767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing